Last updated on April 19, 2014 at 21:20 EDT

Cumberland Pharmaceuticals Reports Third Quarter Financial Results

November 5, 2013

- Omeclamox-Pak® introduced as fourth commercial product

NASHVILLE, Tenn., Nov. 5, 2013 /PRNewswire/ — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

Net Revenue: For the three months ended September 30, 2013, net revenue was $6.5 million compared to $12.5 million for the prior year period. Net revenue was $3.8 million for Acetadote, $2.2 million for Kristalose and $0.5 million for Caldolor.

For the nine months ended September 30, 2013, net revenue was $23.9 million compared with $35.2 million for the nine months ended September 30, 2012.

Operating Expenses: Total operating expenses for the three months ended September 30, 2013, were $8.0 million compared to $9.6 million during the prior year period.

For the nine months ended September 30, 2013, operating expenses were $25.2 million compared to $29.6 million for the prior year period.

Net Income (Loss): Net income (loss) attributable to common shareholders for the three months ended September 30, 2013, was $(0.8) million, or $(0.04) per diluted share.

For the nine months ended September 30, 2013, net income attributable to common shareholders was $(0.6) million, or $(0.03) per diluted share.

Cash Flow: Operating cash flows for the nine months ended September 30, 2013, were $0.9 million, compared to $5.1 million, for the prior year period.

Balance Sheet: As of September 30, 2013, Cumberland had $65.2 million in cash and marketable securities, with approximately $46.0 million in cash and equivalents and $19.2 million in marketable securities. Total assets at September 30, 2013, were $91.9 million.

“The recent addition of Omeclamox-Pak reflects our commitment to the expansion of our product portfolio and to help improve patient care,” said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. “This important new development also reflects the successful implementation of our strategic plan.”

Product Highlights

)Posters with data from three Caldolor studies were presented at the Annual Meeting of the American Society of Anesthesiologists in San Francisco in October 2013. The poster presentations were presented by Dr. Alberto Uribe, Post-Doctoral Researcher, Department of Anesthesiology, Wexner Medical Center at the Ohio State University.

A poster entitled “Multicenter, Open-label Surveillance Trials to Evaluate the Safety and Efficacy of a Shortened Infusion Time of Intravenous Ibuprofen” was presented. Two registry studies made up this presentation. In the first registry study eligible patients were enrolled to receive one of two dose strengths (400 mg for treatment of fever, 800 mg for treatment of pain) of intravenous ibuprofen for up to a 24- hour dosing period. One hundred fifty patients from 13 clinical sites were enrolled in this study. Intravenous ibuprofen reduced fever and pain and the shortened infusion time was well tolerated.

The second registry study was a phase IV multi-center, open-label surveillance clinical study to assess the safety of ibuprofen administered intravenously over five to ten minutes to adult hospitalized patients undergoing surgical procedures. Eligible patients were enrolled to receive 800 mg of intravenous ibuprofen administered at induction of anesthesia and could continue Caldolor therapy for up to 24 hours. Three hundred patients from 21 clinical sites were enrolled in this study. The shortened infusion time was well tolerated.

Another poster presentation was entitled A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery.” This study was conducted at the Ohio State University Medical Center. The study enrolled fifty-one patients and the results indicate, compared to patients receiving ketorolac, patients receiving intravenous ibuprofen experienced less postoperative pain prior to discharge. Patients receiving Caldolor also needed fewer narcotics and were less likely to require narcotics prior to discharge. This data supports the benefits of using Caldolor in a preemptive model of multimodal analgesia.

Cumberland recently announced an agreement with Pernix Therapeutics LLC for the promotion of Omeclamox-Pak covering the United States. Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. It is the only FDA approved triple combination medication to contain omeprazole as the proton pump inhibitor and is prescribed over a shortened treatment period of ten days.

Under the terms of the agreement, Cumberland will promote the product to gastroenterologists across the United States through its field sales force, which also promotes its Kristalose brand. Pernix will promote the product through its specialty sales force focusing on select primary care physicians. The companies will cooperate in the marketing and other activities needed to support the commercialization of the brand.

Conference Call and Webcast
A conference call and live Internet webcast will be held on Tuesday, November 5, 2013 at 4:30 p.m. Eastern Time to discuss the Company’s third quarter 2013 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 91716682. The live webcast and rebroadcast can be accessed via Cumberland’s website at http://investor.shareholder.com/cpix/events.cfm.

About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company’s primary target markets include hospital acute care and gastroenterology. Cumberland’s marketed products include Acetadote(® )(acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor(® )(ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose(® )(lactulose) for Oral Solution, a prescription laxative and Omeclamox-Pak(®) for the treatment of H. pylori and duodenal ulcer disease to eradicate H. pylori. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company’s website at www.cumberlandpharma.com.

About Acetadote
Acetadote is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death. For full prescribing information, visit www.acetadote.com.

About Caldolor
Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Kristalose
Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

About Omeclamox-Pak
Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. Omeclamox-Pak was approved by the U.S. Food and Drug Administration in 2011.

About Helicobacter pylori
H. pylori
is a bacterium acquired largely by people living in developing countries. Researchers suspect the bacteria are passed through contact with human saliva and waste, or contaminated food and water. If H. pylori is left untreated, it can damage the stomach and small intestine wall causing peptic ulcer disease, specifically duodenal ulcers. Symptoms of H. pylori-induced duodenal ulcers generally surface in adults and may include burning pain in the abdomen, nausea, vomiting, bloating, and weight loss. Nearly two-thirds of the world population is infected with H. pylori, including 50 percent of adults older than age 60 and 20 percent of adults under 40 years old.

About Duodenal Ulcers
Despite common belief, healthcare providers do not attribute the cause of duodenal ulcers to stress, alcohol consumption or spicy foods, though all can further inflame the small intestine wall. Patients with duodenal ulcers caused by H. pylori can be diagnosed through a series of simple tests, including blood, urea breath and stool antigen sampling. Other more invasive procedures can include both an upper gastrointestinal (GI) series and endoscopy. Patients who suffer severe abdominal pains, or blood in stool or vomit, may have ulcers which perforated the duodenal wall.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland’s products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company’s most recent Form 10-K and subsequent 10-Q’s as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.


                                        Condensed Consolidated Balance Sheets


                                                                     September 30,              December
                                                                              2013                 2012
                                                                              ----                 ----


    Current assets:

    Cash and cash equivalents                                                       $46,011,203          $54,349,381

    Marketable securities                                               19,163,442                16,686,136

    Accounts receivable, net of allowances                               4,194,415                6,017,201

    Inventories                                                          5,435,613                6,218,355

    Other current assets                                                 3,465,791                3,961,169
                                                                         ---------                ---------

    Total current assets                                                78,270,464                87,232,242

    Property and equipment, net                                            975,016                1,188,914

    Intangible assets, net                                              11,235,866                9,476,798

    Other assets                                                         1,429,951                695,777
                                                                         ---------                -------

    Total assets                                                                    $91,911,297          $98,593,731
                                                                                    ===========            =========


    Current liabilities:

    Accounts payable                                                                 $2,272,018           $2,790,554

    Other current liabilities                                            3,139,884                5,264,806
                                                                         ---------                ---------

    Total current liabilities                                            5,411,902                8,055,360

    Revolving line of credit                                             4,859,951                4,359,951

    Other long-term liabilities                                            707,062                611,933
                                                                           -------                -------

    Total liabilities                                                   10,978,915                13,027,244
                                                                        ----------                ----------

    Commitments and contingencies


    Shareholders' equity:

    Common stock-no par value; 100,000,000 shares
     authorized; 18,157,957 and 18,937,107 shares
     issued and outstanding as of September 30, 2013
     and December 31, 2012, respectively                                63,203,085                67,197,167

    Retained earnings                                                   17,894,903                18,499,154
                                                                        ----------                ----------

    Total shareholders' equity                                          81,097,988                85,696,321

    Noncontrolling interests                                              (165,606)               (129,834)
                                                                          --------                --------

    Total equity                                                        80,932,382                85,566,487
                                                                        ----------                ----------

    Total liabilities and equity                                                    $91,911,297          $98,593,731
                                                                                    ===========            =========

                                            CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

                            Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)


                                                 Three months ended September                     Nine months ended
                                                              30,                                 September 30,
                                                ----------------------------                    ------------------

                                                        2013                         2012                         2013                2012
                                                        ----                         ----                         ----                ----

    Net revenues                                              $6,528,575                   $12,531,719                  $23,867,795         $35,154,871

    Costs and expenses:

    Cost of products sold                          1,030,943                      921,862                    3,294,411               2,873,417

    Selling and marketing                          3,410,205                    4,914,551                   10,626,193               15,387,068

    Research and development                       1,440,584                    1,696,592                    4,276,206               4,653,957

    General and administrative                     1,958,629                    1,890,849                    6,389,569               6,303,392

    Amortization                                     202,982                      128,702                      610,677               371,928
                                                     -------                      -------                      -------               -------

    Total costs and expenses                       8,043,343                    9,552,556                   25,197,056               29,589,762
                                                   ---------                    ---------                   ----------               ----------

    Operating (loss) income                       (1,514,768)                   2,979,163                   (1,329,261)              5,565,109

    Interest income                                   20,350                      107,719                      161,709               256,074

    Interest expense                                 (24,286)                     (17,222)                     (62,721)              (56,369)
                                                     -------                      -------                      -------               -------

    (Loss) income before income
     taxes                                        (1,518,704)                   3,069,660                   (1,230,273)              5,764,814

    Income tax benefit
     (expense)                                       686,209                   (1,207,504)                     590,250                (1,752,563)
                                                     -------                   ----------                      -------               ----------

    Net (loss) income                               (832,495)                   1,862,156                     (640,023)              4,012,251

    Net loss at subsidiary
     attributable to
     noncontrolling interests                         12,553                        7,338                       35,772               24,741
                                                      ------                        -----                       ------               ------

    Net (loss) income
     attributable to common
     shareholders                                              $(819,942)                   $1,869,494                    $(604,251)         $4,036,992
                                                                ========                    ==========                    =========          ==========

    Earnings (loss) per share attributable
     to common shareholders

    - basic                                                       $(0.04)                        $0.10                       $(0.03)              $0.20

    - diluted                                                     $(0.04)                        $0.10                       $(0.03)              $0.20

    Weighted-average shares outstanding

    - basic                                       18,233,407                   19,432,715                   18,420,465               19,737,216

    - diluted                                     18,233,407                   19,670,741                   18,420,465               19,969,051

    Comprehensive (loss) income                                $(832,495)                   $1,862,156                    $(640,023)         $4,012,251
                                                                ========                    ==========                    =========          ==========

                                                                CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

                                                                 Condensed Consolidated Statements of Cash Flows


                                                                                                                        Nine months ended
                                                                                                                          September 30,

                                                                                                                        2013                2012
                                                                                                                        ----                ----

    Cash flows from operating activities:

    Net (loss) income                                                                                                           $(640,023)         $4,012,251

    Adjustments to reconcile net (loss) income to net cash provided by operating activities:

    Depreciation and amortization expense                                                                            917,012               664,369

    Deferred tax benefit                                                                                             (76,332)                 -

    Share-based compensation                                                                                         480,806               556,704

    Excess tax expense (benefit) derived from exercise of stock options                                              511,908                (2,176,222)

    Noncash interest expense                                                                                          12,038               16,050

    Noncash investment losses (gains)                                                                                135,296               (99,286)

    Net changes in assets and liabilities affecting operating activities:

    Accounts receivable                                                                                            1,822,786               1,615,435

    Inventory                                                                                                        782,742                (1,736,947)

    Other current assets and other assets                                                                           (177,754)               (1,228,382)

    Accounts payable and other current liabilities                                                               (2,942,455)               4,178,708

    Other long-term liabilities                                                                                      112,737               (655,201)
                                                                                                                     -------               --------

    Net cash provided by operating activities                                                                        938,761               5,147,479
                                                                                                                     -------               ---------

    Cash flows from investing activities:

    Additions to property and equipment                                                                              (92,435)              (293,693)

    Purchases of marketable securities                                                                           (4,371,508)                (18,849,492)

    Proceeds from sale of marketable securities                                                                    1,758,906               389,302

    Additions to intangible assets                                                                               (2,600,266)                (1,621,100)
                                                                                                                  ----------               ----------

    Net cash used in investment activities                                                                       (5,305,303)                (20,374,983)
                                                                                                                  ----------               ----------

    Cash flows from financing activities:

    Net borrowings (repayments) on line of credit                                                                    500,000               (500,000)

    Exercise of stock options                                                                                        (41,292)              580,101

    Excess tax (expense) benefit derived from exercise of stock options                                             (511,908)              2,176,222

    Repurchase of common shares                                                                                  (3,918,436)                (6,826,394)
                                                                                                                  ----------               ----------

    Net cash used in financing activities                                                                        (3,971,636)                (4,570,071)
                                                                                                                  ----------               ----------

    Net decrease in cash and cash equivalents                                                                    (8,338,178)                (19,797,575)

    Cash and cash equivalents at beginning of period                                                              54,349,381               70,599,146
                                                                                                                  ----------               ----------

    Cash and cash equivalents at end of period                                                                                $46,011,203         $50,801,571
                                                                                                                                =========           =========

    Supplemental disclosure of cash flow information:

    Non-cash investing and financing activities:

    Net change in unpaid additions to intangibles, property and equipment                                                        $230,522             $95,272

SOURCE Cumberland Pharmaceuticals Inc.

Source: PR Newswire